LNP-1892

LNP-1892 is an investigational lipid nanoparticle (LNP) formulation designed for the delivery of therapeutic nucleic acids, specifically messenger RNA (mRNA). Developed by LNP Therapeutics (a subsidiary of Nitto Denko), this platform utilizes proprietary ionizable lipids to encapsulate mRNA, protecting it from degradation and facilitating its entry into target cells. The mechanism of action involves the endosomal uptake of the LNP, followed by the release of the mRNA cargo into the cytoplasm, where it is translated into functional proteins. LNP-1892 has been primarily explored for applications in oncology and infectious diseases, aiming to leverage the body's own cellular machinery to produce therapeutic or antigenic proteins. The formulation is optimized for high encapsulation efficiency and low immunogenicity to enhance the safety and efficacy of mRNA-based therapies.